Al-Husry,Ali Purchases 50,000 Shares of Hikma Pharmaceuticals Plc (HIK) Stock
Hikma Pharmaceuticals Plc (LON:HIK) insider Al-Husry,Ali bought 50,000 shares of the firm’s stock in a transaction on Friday, September 16th. The shares were bought at an average price of GBX 2,119 ($27.66) per share, for a total transaction of £1,059,500 ($1,382,978.72).
Al-Husry,Ali also recently made the following trade(s):
- On Wednesday, August 31st, Al-Husry,Ali bought 140,000 shares of Hikma Pharmaceuticals Plc stock. The shares were bought at an average price of GBX 2,150 ($28.06) per share, for a total transaction of £3,010,000 ($3,928,990.99).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 2152.00 on Tuesday. The firm’s market cap is GBX 4.86 billion. The company has a 50-day moving average of GBX 2,252.71 and a 200 day moving average of GBX 2,229.68. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1,575.00 and a 52 week high of GBX 2,703.00.
Several equities research analysts have commented on HIK shares. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 2,300 ($30.02) target price on shares of Hikma Pharmaceuticals Plc in a research report on Wednesday, June 1st. Stifel Nicolaus restated a “buy” rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, June 24th. Jefferies Group boosted their target price on shares of Hikma Pharmaceuticals Plc from GBX 2,380 ($31.07) to GBX 2,800 ($36.55) and gave the stock a “buy” rating in a research report on Tuesday, July 5th. Morgan Stanley initiated coverage on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, July 21st. They set an “equal weight” rating and a GBX 2,700 ($35.24) target price on the stock. Finally, Numis Securities Ltd initiated coverage on shares of Hikma Pharmaceuticals Plc in a research report on Friday, July 22nd. They issued an “add” rating and a GBX 2,830 ($36.94) price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has an average rating of “Buy” and an average price target of GBX 2,520.90 ($32.91).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.